Axitinib - ≥99%, high purity , Vascular endothelial growth factor receptor inhibitor, CAS No.319460-85-0, Vascular endothelial growth factor receptor inhibitor

Item Number

A129732

• Synonyms: AG13736 | AG-13736 | Benzamide, N-methyl-2-((3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazo)-6-yl)thio)- | NCGC00241108-04 | N-methyl-2-({3-[(1E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide | SR-01000941566 | SR-01000941566-1 | BRD-K29905972-00
• Specifications & Purity: Moligand™, ≥99%
• Biochemical and Physiological Mechanisms: Potent inhibitor of VEGFR-2, -3, and -1 (IC50values are 0.2, 0.1-0.3, and 1.2 nM respectively). Exhibits minimal activity against a panel of ~100 protein kinase. Inhibits angiogenesis and vascular permeability. Also a high affinity BCR-ABL1 (T315I) inhibi
• Legal Information: Sold for research purposes under agreement from Pfizer Inc. - Not for human or veterinary use.
• Storage Temp: Protected from light,Store at -20°C
• Shipped In: Ice chest + Ice pads
• Grade: Moligand™
• Action Type: INHIBITOR
• Mechanism of action: Vascular endothelial growth factor receptor inhibitor

Product Description

Axitinib is a non-selective receptor kinase inhibitor of Flt and Flk proteins. This compound also inhibits Flt-1(VEGFR-1), Flk-1(VEGFR-2), Flt-4(VEGFR-3), PDGFR-β and c-Kit(c-KIT) with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively. Axitinib is studied as an antitumor agent of various cell lines. Axitinib is an inhibitor of PDGFR-β.An inhibitor of Flt and Flk (VEGFR) with antitumor properties

Application：

Axitinib has been used as a vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) to study its effect on renal cancer cell proliferation in vitro. It has also been used to inhibit anterior mesenteric artery (AMA) angiogenesis in dechlorinated embryos maintained in conditioned water (CW).